Study to investigate the benefit-risk ratio of treatment of relapsing-remitting multiple sclerosis (RRMS) by Natalizumab compared against fingolimod, interferon-β, and no treatment across progressive multifocal leukoencephalopathy risk sub-groups.

Trial Profile

Study to investigate the benefit-risk ratio of treatment of relapsing-remitting multiple sclerosis (RRMS) by Natalizumab compared against fingolimod, interferon-β, and no treatment across progressive multifocal leukoencephalopathy risk sub-groups.

Completed
Phase of Trial: Phase IV

Latest Information Update: 17 Dec 2015

At a glance

  • Drugs Natalizumab (Primary) ; Fingolimod; Interferon beta
  • Indications Multiple sclerosis
  • Focus Therapeutic Use
  • Most Recent Events

    • 17 Dec 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top